



## Tazorac<sup>®</sup> (tazarotene) – First-time generic

- On April 4, 2017, Taro Pharmaceuticals launched an [AB-rated](#) generic version of Allergan's [Tazorac \(tazarotene\)](#) 0.1% topical cream.
- Tazorac 0.1% topical cream is indicated for the topical treatment of patients with plaque psoriasis and acne vulgaris.
- Brand Tazorac is also available as topical [cream](#) (0.05%) and [gel](#) (0.05% and 0.1%).
  - The 0.05% cream is indicated for plaque psoriasis but not for acne vulgaris.
  - The 0.05% and 0.1% gels are indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement.
  - The 0.1% gel is also indicated for the treatment of facial acne vulgaris of mild to moderate severity.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.